Assessing patients before initiating

Dosing and ramp-up

Monitoring for TLS and toxicities

Learn about VENCLEXTA’s mechanism of action

Contact

Discover more about how we can help you in your practice.


PBS Information

Venclexta: VENCLEXTA (venetoclax) in combination with rituximab is PBS listed for relapsed or refractory chronic lymphocytic leukaemia (CLL). VENCLEXTA in combination with obinutuzumab is PBS listed for first line treatment of CLL or small lymphocytic lymphoma (SLL). VENCLEXTA in combination with azacitidine is PBS listed for treatment of acute myeloid leukaemia (AML). General Schedule listing. Authority required (telephone). Refer to PBS schedule for full authority information. VENCLEXTA monotherapy is not listed on the PBS. VENCLEXTA in combination with low-dose cytarabine is not listed on the PBS for treatment of AML.

Please review the full Product Information (PI) before prescribing, available below.

AML: acute myeloid leukaemia. AZA: azacitidine. CI: confidence interval. HR: hazard ratio. ITT: intention-to-treat. TLS: tumour lysis syndrome. VEN: VENCLEXTA. 

AU-VENA-210066. Last revised September 2022